Head Injury Treatment (HIT): Perspectives and Comments
Received Date: August 24, 2021; Published Date:October 06, 2021
Behaviors vary significantly from subject to subject when considering traumatic brain injury (TBI)/ chronic traumatic encephalopathy (CTE) with different clinical/behavioral findings involving genetic factors contributing to autism, OCD tendencies, inhibitions and altered with sensory sensitivities which may impact treatment. Novel recommendations were implemented during a case study of an adult male with blunt force induced acute head injury with altered recall of sense memory attributes to initiate past recognitions, music, literature, and visual arts. Subject responded well with certain medications in the recovery from brain injury including: Doxylamine succinate Acetaminophen, Dextromethorphan, Phenylephrine and Cannabidiol (CBD) but performed poorly with Ibuprofen, Fentanyl, Celecxib, Chlorpromazine, Alprazolam (a Fetanyl derivative), Acetyl fentanyl, and Beta-hydroxy-3-methylfentanyl, Tramadol hydrochloride, and Naproxen. These medication responses may indicate possible changes in drug metabolism due to differences in liver enzymes that break down medications and may require pharmacogenetics testing ostensibly prior to treatment.
Keywords: Traumatic Brain Injury (TBI); Chronic Traumatic Encephalopathy (CTE); Head Injury; Brain Injury; Genetic Testing; Brain Scan; Behavior